Federal Investment in Biomedical Research:
The National Institutes of Health

Federal investment in medical research in the United States through the National Institutes of Health (NIH) has led to the development of numerous diagnostic tools and therapies for a wide variety of chronic diseases, including lymphoma, and has advanced our understanding of the etiology of these diseases.

Greater federal support for biomedical research at NIH, including significant growth in funding for the National Cancer Institute (NCI), is necessary to provide investigators with the resources they require to accelerate the progress of research that will ultimately lead to new and innovative treatments for lymphoma and other cancer types.

Advocate Update:

On July 24, 2009, the U.S. House of Representatives voted to approve the Labor-Health and Human Services-Education Appropriations bill. The House provided a total of $31.258 to NIH. This total includes $5.15 billion for NCI.

The Senate Appropriations Committee approved its version of the FY 2010 bill on July 30, 2009. The Senate Committee provided a total of $30.758 billion to NIH, including $5.054 for NCI. Floor action on the Senate bill will be delayed until this fall..